|
WO2021020945A1
|
|
Anticancer agent and method for preparation of porous silica particle
|
|
KR20210015717A
|
|
Anticancer drug and preparing method for porous silica particle
|
|
KR20200043944A
|
|
Bioactive substance deleviry carrier
|
|
KR20200103568A
|
|
Composition for immune enhancing or preventing or treating of cancer
|
|
WO2020171680A1
|
|
Pharmaceutical composition for immune activity or for preventing or treating cancer
|
|
WO2020027641A1
|
|
Pharmaceutical composition for preventing or treating atopic diseases
|
|
KR20200015882A
|
|
Pharmaceutical composition for preventing or treating atopic diseases
|
|
KR20200014704A
|
|
Medicinal composition for treating wound
|
|
WO2020027585A2
|
|
Polypeptide delivery composition
|
|
WO2020027571A1
|
|
Pharmaceutical composition for wound healing
|
|
KR20200014708A
|
|
Composition for delivering of polypptide
|
|
WO2020032366A1
|
|
Immunoreactant carrier
|
|
AU2019317939A1
|
|
Immunoreactant carrier
|
|
WO2020027640A1
|
|
Composition for inhibiting ctgf expression
|
|
KR20200014684A
|
|
Composition for inhibiting CTGF expression
|
|
WO2019209035A1
|
|
Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
|
|
KR20190125943A
|
|
Medicinal composition for preventing or treating flavivirus infections and method for treating the same
|
|
KR20190095088A
|
|
Bioactive substance deleviry carrier
|
|
WO2019050283A1
|
|
Composition for regulating cell fate
|
|
US2019071314A1
|
|
Composition for modulating cell fate
|
